Novomed, a company controlled by Prof. Ronald Li, CEO and a director of Novoheart, completed the acquisition of Novoheart Holdings, a global stem cell biotechnology company, for C$100m. Following closing of the transaction, Novoheart shares were de-listed from the TSXV.